[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 39 of about 39
1. Carson KA, Grossman SA, Fisher JD, Shaw EG: Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol; 2007 Jun 20;25(18):2601-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials.
  • Similar analyses in patients with recurrent glioma could affect the design and conduct of clinical trials substantially.
  • PATIENTS AND METHODS: Between 1995 and 2002, 333 adults with recurrent gliomas were enrolled onto 10 phase I or II trials of systemic or local therapy.
  • The studies had similar inclusion criteria and were conducted within the New Approaches to Brain Tumor Therapy CNS Consortium.
  • RESULTS: Factors associated with an increased risk of death were increased age, lower Karnofsky performance score (KPS), initial and on-study histologies of glioblastoma multiforme (GBM), corticosteroid use, shorter time from original diagnosis to recurrence, and tumor outside frontal lobe.
  • Median survival time was poorest in non-GBM patients with KPS less than 80 or GBM patients, age 50 years, corticosteroid use (4.4 months; 95% CI, 3.6 to 5.4 months); median survival was best in patients with initial histology other than GBM with KPS 80 and tumor confined to the frontal lobe (25.7 months; 95% CI, 18.7 to 52.5), and was 7.0 months (95% CI, 6.2 to 8.0 months) for all patients.
  • CONCLUSION: Initial histology, age, KPS, and corticosteroid use are prognostic for survival in recurrent glioma patients.

  • Genetic Alliance. consumer health - Glioma.
  • Genetic Alliance. consumer health - Brain Tumor, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3260-6 [11432894.001]
  • [Cites] Neuro Oncol. 2000 Jan;2(1):29-33 [11302251.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Front Radiat Ther Oncol. 1999;33:150-7 [10549485.001]
  • [Cites] J Clin Oncol. 2007 Feb 1;25(4):399-404 [17264335.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5174-81 [16951236.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):177-82 [15831235.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Neuro Oncol. 2005 Jan;7(1):32-40 [15701280.001]
  • [Cites] Anticancer Res. 1998 Mar-Apr;18(2B):1303-11 [9615807.001]
  • [Cites] Acta Oncol. 1996;35 Suppl 8:123-7 [9073058.001]
  • [Cites] J Clin Epidemiol. 1995 May;48(5):675-89 [7730923.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2267-76 [11980997.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1845-9 [12721262.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2940-9 [12912940.001]
  • [Cites] J Neurosurg. 2003 Aug;99(2):297-303 [12924704.001]
  • [Cites] Strahlenther Onkol. 2003 Sep;179(9):615-9 [14628127.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):21-7 [14769136.001]
  • [Cites] Neuro Oncol. 2004 Jul;6(3):227-35 [15279715.001]
  • [Cites] Mol Ther. 2004 Nov;10(5):958-66 [15509513.001]
  • [Cites] J Clin Oncol. 1983 Jan;1(1):38-44 [6321671.001]
  • [Cites] Acta Oncol. 1989;28(1):51-5 [2539846.001]
  • [CommentIn] J Clin Oncol. 2012 Feb 10;30(5):562-3; author reply 563-4 [22215743.001]
  • (PMID = 17577040.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062475; United States / NCI NIH HHS / CA / CA62475
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS507874; NLM/ PMC4118746
  •  go-up   go-down


2. Fouladi M, Stewart CF, Blaney SM, Onar-Thomas A, Schaiquevich P, Packer RJ, Gajjar A, Kun LE, Boyett JM, Gilbertson RJ: Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study. J Clin Oncol; 2010 Sep 20;28(27):4221-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.
  • PURPOSE: To estimate the maximum-tolerated dose, dose-limiting toxicities (DLTs), and pharmacokinetic properties of lapatinib, a selective epidermal growth factor receptor (EGFR) and ERBB2 inhibitor, in children with refractory or recurrent CNS malignancies.
  • Expression of the four ERBB receptors and downstream signaling elements in tumor tissue was evaluated by immunohistochemistry.
  • CONCLUSION: Lapatinib is well tolerated in children with recurrent CNS malignancies, with rash, diarrhea, and fatigue identified as DLTs.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Central Nervous System Neoplasms / drug therapy. Protein Kinase Inhibitors / administration & dosage. Quinazolines / administration & dosage
  • [MeSH-minor] Administration, Oral. Adolescent. Child. Child, Preschool. Diarrhea / chemically induced. Exanthema / chemically induced. Fatigue / chemically induced. Female. Humans. Infant. Male. Maximum Tolerated Dose. Phosphorylation. Receptor, Epidermal Growth Factor / analysis. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, ErbB-2 / analysis. Receptor, ErbB-2 / antagonists & inhibitors. Steroids / therapeutic use. Treatment Outcome. United States. Young Adult

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 2000 Jul 3;19(13):3159-67 [10880430.001]
  • [Cites] Cancer Chemother Pharmacol. 2010 Jan;65(2):353-61 [19499221.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • [Cites] Oncogene. 2002 Sep 12;21(41):6255-63 [12214266.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3054-64 [12374672.001]
  • [Cites] Mol Cancer Ther. 2001 Dec;1(2):85-94 [12467226.001]
  • [Cites] Lancet Oncol. 2003 Jul;4(7):397-406 [12850190.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3620-4 [14506149.001]
  • [Cites] Mol Cell. 2003 Sep;12(3):541-52 [14527402.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):984-93 [14970185.001]
  • [Cites] Cancer Cell. 2004 Apr;5(4):317-28 [15093539.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jun 18;319(1):1-11 [15158434.001]
  • [Cites] Oncologist. 2004;9 Suppl 3:10-5 [15163842.001]
  • [Cites] Mol Cell Biol. 1989 Mar;9(3):1165-72 [2566907.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4838-48 [9354447.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):786-92 [15728811.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):341-54 [15864276.001]
  • [Cites] J Clin Oncol. 2005 Aug 10;23(23):5305-13 [15955900.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Feb 2;831(1-2):169-75 [16364699.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1630-9 [16452222.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Jul;7(7):505-16 [16829981.001]
  • [Cites] Trends Cell Biol. 2006 Dec;16(12):649-56 [17085050.001]
  • [Cites] N Engl J Med. 2006 Dec 28;355(26):2733-43 [17192538.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3137-43 [17634493.001]
  • [Cites] J Clin Oncol. 2007 Aug 10;25(23):3397-8 [17635950.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3753-8 [17704424.001]
  • [Cites] J Clin Oncol. 2008 Apr 20;26(12):1993-9 [18421051.001]
  • [Cites] Semin Oncol. 2008 Jun;35(3):286-97 [18544443.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4484-90 [18628463.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4921-7 [18794549.001]
  • [Cites] Clin Cancer Res. 2009 Feb 15;15(4):1452-9 [19228746.001]
  • [Cites] J Biopharm Stat. 2009;19(3):437-55 [19384687.001]
  • [Cites] Clin Pharmacol Ther. 2000 Oct;68(4):356-66 [11061575.001]
  • (PMID = 20713864.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA129541; United States / NCI NIH HHS / CA / U01 CA081457; United States / NCI NIH HHS / CA / U01CA81457
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 0 / Steroids; 0VUA21238F / lapatinib; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2953974
  •  go-up   go-down


3. Bertalanffy A, Roessler K, Koperek O, Gelpi E, Prayer D, Knosp E: Recurrent central neurocytomas. Cancer; 2005 Jul 1;104(1):135-42
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent central neurocytomas.
  • BACKGROUND: Since the first description of Central neurocytomas (CNs) as a benign tumor entity in 1982, there has been great enthusiasm regarding the benign course and the curative surgical approach to this disease.
  • RESULTS: Between 1985-2003. surgical resection was performed in 14 patients with CNs ages 16-43 years (7 were female and 7 were male).
  • The MIB-1 proliferation index ranged from 0.8-11% (median of 4.6%), but was reported to be 46.8% in the malignant transformed tumor.
  • CONCLUSIONS: CNs appear to have a higher tendency to recur during long-term follow-up than previously reported, even after complete resection.
  • [MeSH-major] Brain Neoplasms / epidemiology. Neoplasm Recurrence, Local / epidemiology. Neurocytoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / analysis. Female. Follow-Up Studies. Humans. Male. Retrospective Studies. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15880432.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


Advertisement
4. Phuphanich S, Carson KA, Grossman SA, Lesser G, Olson J, Mikkelsen T, Desideri S, Fisher JD, New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium: Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma. Neuro Oncol; 2008 Aug;10(4):617-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma.
  • Patients with recurrent malignant glioma received oral atrasentan at >or=10 mg/day.
  • Patients were evaluated for response every 8 weeks and remained on the study until the tumor progressed or toxicities occurred.
  • We conclude that the MTD of daily oral atrasentan in patients with recurrent malignant glioma is 70 mg/day.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuro Oncol. 2006 Jan;8(1):27-37 [16443945.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Br J Clin Pharmacol. 2000 Jun;49(6):562-73 [10848720.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Br J Clin Pharmacol. 2002 Apr;53(4):355-62 [11966665.001]
  • [Cites] J Biol Chem. 2002 Aug 2;277(31):27850-5 [12023962.001]
  • [Cites] Nat Rev Drug Discov. 2002 Dec;1(12):986-1001 [12461520.001]
  • [Cites] Nat Rev Cancer. 2003 Feb;3(2):110-6 [12563310.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):679-89 [12586806.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):906-11 [12615701.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2965-72 [12912943.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4406-11 [15240529.001]
  • [Cites] Cancer Chemother Rep. 1974 Nov-Dec;58(6):787-92 [4447922.001]
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] Peptides. 1993 Mar-Apr;14(2):385-99 [8483816.001]
  • [Cites] J Neurochem. 1994 Dec;63(6):2240-7 [7964744.001]
  • [Cites] J Cardiovasc Pharmacol. 1995;26 Suppl 3:S408-11 [8587429.001]
  • [Cites] J Pharmacol Exp Ther. 1996 Feb;276(2):473-81 [8632312.001]
  • [Cites] Biochim Biophys Acta. 1996 May 28;1311(3):155-63 [8664342.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Apr;56(4):435-9 [9100674.001]
  • [Cites] N Engl J Med. 1998 Mar 19;338(12):784-90 [9504938.001]
  • [Cites] Ann Neurol. 1998 Oct;44(4):691-5 [9778271.001]
  • [Cites] Circulation. 1998 Nov 24;98(21):2262-8 [9826312.001]
  • [Cites] Neuro Oncol. 2005 Jan;7(1):32-40 [15701280.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • (PMID = 18477765.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062406; United States / NCI NIH HHS / CA / U01 CA062475; United States / NCI NIH HHS / CA / U01-CA62406; United States / NCI NIH HHS / CA / UO1 CA-62475
  • [Publication-type] Case Reports; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Pyrrolidines; V6D7VK2215 / atrasentan
  • [Other-IDs] NLM/ PMC2666236
  •  go-up   go-down


5. Kamoshima Y, Sawamura Y, Ikeda J, Shirato H, Aoyama H: Late recurrence and salvage therapy of CNS germinomas. J Neurooncol; 2008 Nov;90(2):205-11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late recurrence and salvage therapy of CNS germinomas.
  • Central nervous system (CNS) germinoma is a curable tumor and its recurrence rate after initial therapy may be approximately 10% or higher.
  • Twenty-five patients with recurrent germinoma treated at Hokkaido University Hospital were retrospectively reviewed.
  • All patients had been tumor-free for at least 6 months after the initial treatment.
  • Seventeen patients (68%) were salvaged and were tumor-free at the final observation.
  • At first recurrence, 11 patients were treated using radiation therapy with or without surgery and 7 out of the 11 patients died due to the recurrent tumor.
  • On the other hand, 13 patients who received salvage chemotherapy and radiotherapy were tumor-free at the last follow-up.
  • In conclusion, late recurrence is not a rare event in patients with CNS germinoma.
  • [MeSH-major] Central Nervous System Neoplasms / prevention & control. Germinoma / prevention & control. Salvage Therapy / methods
  • [MeSH-minor] Adolescent. Adult. Child. Female. Follow-Up Studies. Humans. Male. Remission Induction. Retrospective Studies. Secondary Prevention. Time Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18604473.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


6. Grossman SA, Carson KA, Phuphanich S, Batchelor T, Peereboom D, Nabors LB, Lesser G, Hausheer F, Supko JG, New Approaches to Brain Tumor Therapy CNS Consortium: Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas. Neuro Oncol; 2008 Aug;10(4):608-16
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas.
  • This phase I clinical trial was conducted to determine the maximum tolerated dose (MTD) of karenitecin in adults with recurrent malignant glioma (MG), to describe the effects of enzyme-inducing antiseizure drugs (EIASDs) on its pharmacokinetics, and to obtain preliminary evidence of activity.
  • Karenitecin was administered intravenously over 60 min daily for 5 consecutive days every 3 weeks to adults with recurrent MG who had no more than one prior chemotherapy regimen.
  • This schedule of karenitecin, a novel lipophilic camptothecin analogue, has little activity in recurrent MG.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Invest New Drugs. 2000 Aug;18(3):275-80 [10958598.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Jun;53(6):527-32 [14997342.001]
  • [Cites] J Med Chem. 2000 Oct 19;43(21):3970-80 [11052802.001]
  • [Cites] Pharm Res. 2000 Dec;17(12):1551-7 [11303967.001]
  • [Cites] Cancer Chemother Pharmacol. 2001 Jul;48(1):83-7 [11488529.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2182-94 [11489791.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):641-61 [11895891.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):980-6 [12095566.001]
  • [Cites] Ann Oncol. 2003 Apr;14(4):603-14 [12649109.001]
  • [Cites] Oncology (Williston Park). 2003 May;17(5 Suppl 5):9-14 [12800600.001]
  • [Cites] Chem Pharm Bull (Tokyo). 1985 Apr;33(4):1620-32 [4042238.001]
  • [Cites] J Clin Oncol. 1994 Sep;12(9):1886-9 [8083712.001]
  • [Cites] J Pharm Sci. 1995 Apr;84(4):518-9 [7629749.001]
  • [Cites] Cancer Chemother Pharmacol. 1996;37(3):195-202 [8529278.001]
  • [Cites] Ann Oncol. 1996 Feb;7(2):205-7 [8777179.001]
  • [Cites] J Biopharm Stat. 1997 Mar;7(1):171-8 [9056596.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;41(6):429-36 [9554585.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;41(6):464-8 [9554590.001]
  • [Cites] Cancer. 1999 Mar 1;85(5):1160-5 [10091802.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):3009-16 [15837755.001]
  • [Cites] Lung Cancer. 2005 Jun;48(3):399-407 [15893009.001]
  • [Cites] Neuro Oncol. 2006 Apr;8(2):189-93 [16533878.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2940-9 [12912940.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):21-7 [14769136.001]
  • [Cites] Int J Cancer. 2000 Oct 15;88(2):260-6 [11004678.001]
  • (PMID = 18577560.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01-CA62475; United States / NCI NIH HHS / CA / U01 CA062475; United States / NCI NIH HHS / CA / P30-CA0516; United States / NCI NIH HHS / CA / U01-CA105689; United States / NCI NIH HHS / CA / U01 CA105689
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antineoplastic Agents; 24R60NVC41 / cositecan; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ PMC2666235
  •  go-up   go-down


7. Weingart J, Grossman SA, Carson KA, Fisher JD, Delaney SM, Rosenblum ML, Olivi A, Judy K, Tatter SB, Dolan ME: Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol; 2007 Feb 1;25(4):399-404
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial.
  • PURPOSE: This phase I trial was designed to (1) establish the dose of O6-benzylguanine (O6-BG) administered intravenously as a continuous infusion that suppresses O6-alkylguanine-DNA alkyltransferase (AGT) levels in brain tumors, (2) evaluate the safety of extending continuous-infusion O6-BG at the optimal dose with intracranially implanted carmustine wafers, and (3) measure the pharmacokinetics of O6-BG and its metabolite.
  • Tumor samples were evaluated for AGT levels.
  • Future trials are required to determine if the inhibition of tumor AGT levels results in increased efficacy.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3025-31 [10955780.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3570-5 [9817277.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7178-87 [16192602.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6307-10 [11103789.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2277-83 [11980998.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1845-9 [12721262.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):28-32 [14769137.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):1871-4 [15041700.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(14):5368-72 [2164681.001]
  • [Cites] Cancer Commun. 1990;2(11):371-7 [2242301.001]
  • [Cites] J Neurosurg. 1991 Mar;74(3):441-6 [1993909.001]
  • [Cites] Cancer Res. 1991 Jul 1;51(13):3367-72 [1647266.001]
  • [Cites] J Neurosurg. 1992 Apr;76(4):640-7 [1545259.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;32(6):471-6 [8258196.001]
  • [Cites] Cancer Res. 1994 Oct 1;54(19):5123-30 [7923129.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 1995;51:167-223 [7659775.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):783-8 [8631014.001]
  • [Cites] Br J Cancer. 1996 Oct;74(7):1030-6 [8855970.001]
  • [Cites] Neurosurgery. 1997 Jul;41(1):44-8; discussion 48-9 [9218294.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1803-10 [9586894.001]
  • [Cites] J Clin Oncol. 2000 Oct 15;18(20):3522-8 [11032594.001]
  • (PMID = 17264335.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA14599; United States / NCI NIH HHS / CA / P30 CA014599; United States / NCI NIH HHS / CA / U01 CA062475; United States / NCRR NIH HHS / RR / M01 RR000055; United States / NCI NIH HHS / CA / U01 CA069852-12; United States / NCRR NIH HHS / RR / M01 RR000055-400764; United States / NCI NIH HHS / CA / CA69852; United States / NCRR NIH HHS / RR / RR000055-400764; United States / NCI NIH HHS / CA / CA069852-12; United States / NCI NIH HHS / CA / P30 CA014599-289015; United States / NCI NIH HHS / CA / CA62475; United States / NCI NIH HHS / CA / U01 CA069852; United States / NCI NIH HHS / CA / CA014599-289015
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / carmustine with prolifeprosan 20; 19916-73-5 / O(6)-benzylguanine; 5Z93L87A1R / Guanine; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; U68WG3173Y / Carmustine
  • [Other-IDs] NLM/ NIHMS66419; NLM/ PMC2556256
  •  go-up   go-down


8. Iwamoto FM, Lamborn KR, Robins HI, Mehta MP, Chang SM, Butowski NA, Deangelis LM, Abrey LE, Zhang WT, Prados MD, Fine HA: Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol; 2010 Aug;12(8):855-61
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).
  • The objective of this phase II single-arm study was to evaluate the efficacy and safety of pazopanib, a multi-targeted tyrosine kinase inhibitor, against vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3, platelet-derived growth factor receptor-alpha and -beta, and c-Kit, in recurrent glioblastoma.
  • Brain magnetic resonance imaging and clinical reassessment were made every 8 weeks.
  • Grade 3/4 toxicities included leukopenia (n = 1), lymphopenia (n = 2), thrombocytopenia (n = 1), ALT elevation (n = 3), AST elevation (n = 1), CNS hemorrhage (n = 1), fatigue (n = 1), and thrombotic/embolic events (n = 3); 8 patients required dose reduction.
  • Two patients had a partial radiographic response by standard bidimensional measurements, whereas 9 patients (6 at the 8-week point and 3 only within the first month of treatment) had decreased contrast enhancement, vasogenic edema, and mass effect but <50% reduction in tumor.
  • [MeSH-major] Angiogenesis Inhibitors / administration & dosage. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Pyrimidines / administration & dosage. Sulfonamides / administration & dosage
  • [MeSH-minor] Administration, Oral. Adult. Aged. Disease Progression. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neovascularization, Pathologic / drug therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4733-40 [19720927.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1083-93 [12651601.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1399-405 [12684411.001]
  • [Cites] J Clin Invest. 2003 May;111(9):1287-95 [12727920.001]
  • [Cites] J Neurosurg. 1977 Sep;47(3):329-35 [894339.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Oct;85(20):7748-52 [2845420.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer Res. 1992 Jun 1;52(11):3213-9 [1317261.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):845-8 [1279432.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5523-34 [15994924.001]
  • [Cites] Cancer Cell. 2006 Apr;9(4):287-300 [16616334.001]
  • [Cites] Cancer Cell. 2006 May;9(5):391-403 [16697959.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4899-907 [16914578.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Cell Oncol. 2007;29(5):399-408 [17726262.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):162-70 [18356283.001]
  • [Cites] N Engl J Med. 2008 Jul 31;359(5):492-507 [18669428.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4659-65 [18824712.001]
  • [Cites] Curr Opin Investig Drugs. 2008 Dec;9(12):1324-35 [19037839.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):740-5 [19114704.001]
  • [Cites] Cancer Cell. 2009 Mar 3;15(3):220-31 [19249680.001]
  • [Cites] PLoS One. 2009;4(4):e5123 [19352490.001]
  • [Cites] J Clin Oncol. 2009 May 20;27(15):2542-52 [19332720.001]
  • [Cites] J Clin Oncol. 2009 Jul 1;27(19):3126-32 [19451427.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):156-63 [19167838.001]
  • [Cites] Neoplasia. 2000 Jul-Aug;2(4):306-14 [11005565.001]
  • (PMID = 20200024.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00459381
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062421-12; United States / NCRR NIH HHS / RR / M01-RR00079; United States / NCI NIH HHS / CA / 5-U01CA62399-09; United States / NCI NIH HHS / CA / U01CA62421-08; United States / NCI NIH HHS / CA / CA62422; United States / NCI NIH HHS / CA / U01 CA062421; United States / NCRR NIH HHS / RR / M01RR03186; United States / NCI NIH HHS / CA / CA62399
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Pyrimidines; 0 / Sulfonamides; 7RN5DR86CK / pazopanib
  • [Other-IDs] NLM/ PMC2940686
  •  go-up   go-down


9. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol; 2007 Oct 20;25(30):4722-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
  • PURPOSE: The prognosis for patients with recurrent glioblastoma multiforme is poor, with a median survival of 3 to 6 months.
  • After this regimen was deemed safe and effective, the irinotecan schedule was changed to an accepted brain tumor regimen of four doses in 6 weeks, in anticipation of a phase III randomized trial of irinotecan versus irinotecan and bevacizumab.
  • One patient developed a CNS hemorrhage, which occurred in his 10th cycle.
  • CONCLUSION: Bevacizumab and irinotecan is an effective treatment for recurrent glioblastoma multiforme and has moderate toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Glioblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Clin Pract Oncol. 2008 Apr;5(4):186-7 [18285760.001]
  • [CommentIn] J Clin Oncol. 2007 Oct 20;25(30):4705-6 [17947716.001]
  • [CommentIn] J Clin Oncol. 2008 Nov 10;26(32):5304-5; author reply 5305 [18854564.001]
  • [CommentIn] Nat Clin Pract Neurol. 2008 May;4(5):242-3 [18212790.001]
  • [CommentIn] J Clin Oncol. 2008 Feb 20;26(6):1012-3; author reply 1013 [18281677.001]
  • (PMID = 17947719.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 4 R37 CA11898; United States / NCI NIH HHS / CA / 5 P50 CA108786; United States / NINDS NIH HHS / NS / 5 P50 NS20023
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


10. Khatua S, Dhall G, O'Neil S, Jubran R, Villablanca JG, Marachelian A, Nastia A, Lavey R, Olch AJ, Gonzalez I, Gilles F, Nelson M, Panigrahy A, McComb G, Krieger M, Fan J, Sposto R, Finlay JL: Treatment of primary CNS germinomatous germ cell tumors with chemotherapy prior to reduced dose whole ventricular and local boost irradiation. Pediatr Blood Cancer; 2010 Jul 15;55(1):42-6
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of primary CNS germinomatous germ cell tumors with chemotherapy prior to reduced dose whole ventricular and local boost irradiation.
  • BACKGROUND: The purpose of this study was to evaluate a reduced irradiation dose strategy for newly diagnosed primary central nervous system (CNS) germinomas.
  • Initial tumor markers for beta-human chorionic gonadotrophin (HCGbeta) and alpha-fetoprotein (AFP) were evaluated in serum and lumbar cerebrospinal fluid (CSF).
  • RESULTS: Eighteen of 20 patients are without evidence of residual or recurrent tumor.
  • Both relapsing patients were subsequently determined to harbor malignant non-germinomatous germ cell tumor (NGGCT).
  • CONCLUSION: Chemotherapy followed by reduced dose whole ventricular and local boost irradiation appears to be effective in patients with localized pure CNS germinoma with evidence of preservation of neurocognitive function.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / therapy. Central Nervous System Neoplasms / therapy. Germinoma / therapy. Neoplasms, Germ Cell and Embryonal / therapy
  • [MeSH-minor] Adolescent. Adult. Carboplatin / adverse effects. Carboplatin / therapeutic use. Child. Child, Preschool. Chorionic Gonadotropin, beta Subunit, Human / blood. Combined Modality Therapy. Dose-Response Relationship, Radiation. Etoposide / adverse effects. Etoposide / therapeutic use. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Retrospective Studies. Young Adult. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20222020.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


11. Kirkpatrick JP, Vredenburgh JJ, Desjardins A, Gururangan S, Peters KB, Boulton ST, Friedman AH, Friedman HS, Reardon DA: Phase I study of vandetanib, imatinib mesylate, and hydroxyurea for recurrent malignant glioma. J Clin Oncol; 2009 May 20;27(15_suppl):e13007

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of vandetanib, imatinib mesylate, and hydroxyurea for recurrent malignant glioma.
  • : e13007 Background: Malignant glioma (MG), an incurable primary CNS tumor, is characterized by frequent aberrant activation of EGFR, VEGFR, and PDGFR.
  • METHODS: Adult recurrent MG patients with ≤ 3 prior recurrences, KPS ≥ 60% and adequate organ function were stratified based on concurrent enzyme-inducing anticonvulsant use (EIAC).
  • CONCLUSIONS: Combination of V, IM, and H is well-tolerated in recurrent MG patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962760.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Gururangan S, Chi SN, Young Poussaint T, Onar-Thomas A, Gilbertson RJ, Vajapeyam S, Friedman HS, Packer RJ, Rood BN, Boyett JM, Kun LE: Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol; 2010 Jun 20;28(18):3069-75
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
  • PURPOSE: A phase II study of bevacizumab (BVZ) plus irinotecan (CPT-11) was conducted in children with recurrent malignant glioma (MG) and intrinsic brainstem glioma (BSG).
  • Toxicities related to BVZ included grade 1 to 3 fatigue in seven patients, grade 1 to 2 hypertension in seven patients, grade 1 CNS hemorrhage in four patients, and grade 4 CNS ischemia in two patients.
  • CONCLUSION: BVZ plus CPT-11 was well-tolerated but had minimal efficacy in children with recurrent malignant glioma and brainstem glioma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Brain Stem Neoplasms / drug therapy. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Child. Diffusion Magnetic Resonance Imaging. Humans. Phosphorylation. Survival Rate. Treatment Outcome. Vascular Endothelial Growth Factor Receptor-2 / metabolism. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Nat Rev Cancer. 2008 Apr;8(4):309-16 [18337733.001]
  • [Cites] Neuro Oncol. 2008 Aug;10(4):624-30 [18539884.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):383-9 [18793954.001]
  • [Cites] Pediatr Blood Cancer. 2008 Dec;51(6):806-11 [18802947.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14(20):6371-5 [18927275.001]
  • [Cites] J Neurooncol. 2009 Feb;91(3):329-36 [18953493.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):740-5 [19114704.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4733-40 [19720927.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1878-86 [10766175.001]
  • [Cites] Oncogene. 2000 Nov 20;19(49):5598-605 [11114740.001]
  • [Cites] Eur J Cancer. 2001 Nov;37(16):2064-72 [11597385.001]
  • [Cites] NMR Biomed. 2002 Feb;15(1):6-17 [11840548.001]
  • [Cites] J Neurooncol. 2002 Jul;58(3):237-53 [12187958.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4684-91 [12488414.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3542; author reply 3543 [12972536.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):271-5 [8508417.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1516-25 [10334539.001]
  • [Cites] J Neurooncol. 1999 May;43(1):43-7 [10448870.001]
  • [Cites] Am J Health Syst Pharm. 2004 Nov 1;61(21 Suppl 5):S21-6 [15552623.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):172-87 [15687360.001]
  • [Cites] Neurol Res. 2005 Jun;27(4):371-7 [15949234.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2347-55 [15985545.001]
  • [Cites] Oncology. 2005;69 Suppl 3:25-33 [16301833.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1364-71 [16463390.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] Cancer. 2007 Oct 1;110(7):1542-50 [17705175.001]
  • (PMID = 20479404.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000188; United States / NCI NIH HHS / CA / U01 CA081457; United States / NCRR NIH HHS / RR / M01RR00188; United States / NCI NIH HHS / CA / U01CA81457
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0H43101T0J / irinotecan; 2S9ZZM9Q9V / Bevacizumab; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ PMC2903337
  •  go-up   go-down


13. Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, Sampson JH, Ram Z, Gutin PH, Gibbons RD, Aldape KD, Croteau DJ, Sherman JW, Puri RK, Cintredekin Besudotox Intraparenchymal Study Group: Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol; 2007 Mar 1;25(7):837-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group.
  • PURPOSE: Glioblastoma multiforme (GBM) is a devastating brain tumor with a median survival of 6 months after recurrence.
  • We assessed the use of intracerebral CED to deliver CB in patients with recurrent malignant glioma (MG).
  • PATIENTS AND METHODS: Three phase I clinical studies evaluated intracerebral CED of CB along with tumor resection.
  • All patients underwent tumor resection followed by a single intraparenchymal infusion (in addition to the intraparenchymal one following resection), with a portion of patients who had a preresection intratumoral infusion.
  • The maximum tolerated intraparenchymal concentration was 0.5 microg/mL and tumor necrosis was observed at this concentration.
  • CB- and procedure-related adverse events were primarily limited to the CNS.
  • [MeSH-minor] Adult. Aged. Catheterization. Convection. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Tissue Distribution

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17327604.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Exotoxins; 0 / IL13-PE38QQR; 0 / Immunotoxins; 0 / Interleukin-13
  •  go-up   go-down


14. Terasaki M, Bouffet E, Katsuki H, Fukushima S, Shigemori M: Pilot trial of the rate of response, safety, and tolerability of temozolomide and oral VP-16 in patients with recurrent or treatment-induced malignant central nervous system tumors. Surg Neurol; 2008 Jan;69(1):46-50
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot trial of the rate of response, safety, and tolerability of temozolomide and oral VP-16 in patients with recurrent or treatment-induced malignant central nervous system tumors.
  • BACKGROUND: The aim of this study was to determine the response and toxicity of patients with recurrent or treatment-induced brain tumors to TMZ and oral VP-16.
  • METHODS: Eleven patients with recurrent or treatment-induced malignant CNS tumors, including treatment-induced PNET (in 1 patient), brainstem glioma (in 3 patients; 1 with treatment-induced, 2 with recurrence), recurrent anaplastic astrocytoma (in 3 patients), and recurrent glioblastoma (in 4 patients) were evaluated in a pilot study of TMZ and oral VP-16 chemotherapy.
  • The histologic subtype of the tumor, its location, and its maximum response to chemotherapy did not have an impact on the duration of disease control.
  • CONCLUSION: This limited pilot study confirms the innocuousness and the activity of the combination of TMZ and oral VP-16 in recurrent malignant brain tumors.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Etoposide / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Neoplasms, Neuroepithelial / drug therapy. Neoplasms, Second Primary / drug therapy
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Aged. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Pilot Projects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18054615.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


15. Phuphanich S, Baker SD, Grossman SA, Carson KA, Gilbert MR, Fisher JD, Carducci MA: Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study. Neuro Oncol; 2005 Apr;7(2):177-82
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study.
  • We determined the maximum tolerated dose (MTD), toxicity profile, pharmacokinetic parameters, and preliminary efficacy data of oral sodium phenylbutyrate (PB) in patients with recurrent malignant gliomas.
  • Twenty-three patients with supratentorial recurrent malignant gliomas were enrolled on this dose escalation trial.
  • This study defines the MTD and recommended phase 2 dose of PB at 27 g/day for heavily pretreated patients with recurrent gliomas.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2292-300 [11489804.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):984-90 [10071293.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):963-70 [11948101.001]
  • [Cites] J Neurooncol. 2002 Sep;59(3):239-42 [12241121.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2940-9 [12912940.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):21-7 [14769136.001]
  • [Cites] Cancer Chemother Biol Response Modif. 1990;11:303-20 [2223397.001]
  • [Cites] J Clin Invest. 1993 May;91(5):2288-95 [8486788.001]
  • [Cites] Cancer Res. 1994 Feb 15;54(4):891-5 [8313377.001]
  • [Cites] Int J Cancer. 1995 Feb 8;60(4):507-14 [7829265.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3121-8 [9294475.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;42(2):118-26 [9654111.001]
  • [Cites] J Natl Cancer Inst. 1998 Nov 4;90(21):1621-5 [9811311.001]
  • [Cites] Clin Cancer Res. 1996 Feb;2(2):379-87 [9816181.001]
  • [Cites] Clin Cancer Res. 1997 Oct;3(10):1755-62 [9815560.001]
  • [Cites] Mayo Clin Proc. 1999 Feb;74(2):137-45 [10069350.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3047-55 [11595694.001]
  • (PMID = 15831235.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062475; United States / NCI NIH HHS / CA / U01 CA 62475
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antineoplastic Agents; 0 / Phenylbutyrates; 9035-51-2 / Cytochrome P-450 Enzyme System
  • [Other-IDs] NLM/ PMC1871887
  •  go-up   go-down


16. da Fonseca CO, Schwartsmann G, Fischer J, Nagel J, Futuro D, Quirico-Santos T, Gattass CR: Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas. Surg Neurol; 2008 Sep;70(3):259-66; discussion 266-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas.
  • The intranasal delivery allows drugs that do not cross the BBB to enter the CNS; moreover, it eliminates the need for systemic delivery, thereby reducing unwanted systemic side effects.
  • METHODS: We are conducting a phase I/II study to evaluate the antitumoral activity of POH intranasal delivery in a 4x daily schedule in patients with recurrent MG.
  • The objective was to determine PFS at 6 months and the safety for POH in adult patients who failed conventional treatment.
  • Perillyl alcohol is well tolerated and regression of tumor size in some patients is suggestive of antitumor activity.
  • [MeSH-major] Administration, Intranasal. Antineoplastic Agents / administration & dosage. Brain Neoplasms / drug therapy. Glioma / drug therapy. Monoterpenes / administration & dosage
  • [MeSH-minor] Antineoplastic Agents, Alkylating / administration & dosage. Blood-Brain Barrier / drug effects. Blood-Brain Barrier / physiology. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Disease Progression. Drug Administration Schedule. Enzyme Inhibitors / administration & dosage. Female. Humans. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / physiopathology. Oncogene Protein p21(ras) / drug effects. Oncogene Protein p21(ras) / genetics. Oncogene Protein p21(ras) / metabolism. Signal Transduction / drug effects. Signal Transduction / physiology. Survival Rate. Transforming Growth Factor beta / drug effects. Transforming Growth Factor beta / genetics. Transforming Growth Factor beta / metabolism. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18295834.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Enzyme Inhibitors; 0 / Monoterpenes; 0 / Transforming Growth Factor beta; 319R5C7293 / perilla alcohol; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 3.6.5.2 / Oncogene Protein p21(ras)
  •  go-up   go-down


17. Grossman SA, Alavi JB, Supko JG, Carson KA, Priet R, Dorr FA, Grundy JS, Holmlund JT: Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas. Neuro Oncol; 2005 Jan;7(1):32-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas.
  • Aprinocarsen is an antisense oligonucleotide against PKC-alpha that reduces PKC-alphain human cell lines and inhibits a human glioblastoma tumor cell line in athymic mice.
  • In this phase 2 study, aprinocarsen was administered to patients with recurrent high-grade gliomas by continuous intravenous infusion (2.0 mg/kg/day for 21 days per month).
  • Their median age was 46 years (range, 28-68 years), median Karnofsky performance status was 80 (range, 60-100), median tumor volume was 58 cm3 (range, 16-254 cm3), and histology included glioblastoma multiforme (n = 16), anaplastic oligodendroglioma (n = 4), and anaplastic astrocytoma (n = 1).
  • No tumor responses were observed.
  • The observed toxicities were mild, reversible, and uncommon (grade 3 thrombocytopenia [n = 3] and grade 4 AST [n = 1]), and no coagulopathy or CNS bleeding resulted from this therapy.
  • The rapid deterioration seen in these patients could result from tumor growth or an effect of aprinocarsen on bloodbrain barrier integrity.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Pharmacol. 1996 Aug;50(2):236-42 [8700129.001]
  • [Cites] Glia. 1999 Feb 1;25(3):240-6 [9932870.001]
  • [Cites] J Biopharm Stat. 1997 Mar;7(1):171-8 [9056596.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3121-8 [9294475.001]
  • [Cites] J Biol Chem. 1998 Mar 13;273(11):6001-4 [9497312.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3586-95 [10550158.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3357-63 [10589745.001]
  • [Cites] Prog Neurobiol. 2001 Feb;63(3):321-36 [11115728.001]
  • [Cites] Curr Oncol Rep. 2000 Sep;2(5):445-53 [11122877.001]
  • [Cites] Neurosci Lett. 2001 Jan 19;297(3):163-6 [11137753.001]
  • [Cites] Brain Res Mol Brain Res. 2001 Nov 1;95(1-2):110-6 [11687282.001]
  • [Cites] Curr Oncol Rep. 2002 Jan;4(1):37-46 [11734112.001]
  • [Cites] Expert Opin Investig Drugs. 2001 Dec;10(12):2117-40 [11772309.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2002 Feb;72(2):262-5 [11796780.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1042-8 [11948111.001]
  • [Cites] Neurosci Lett. 2002 May 17;324(2):105-8 [11988338.001]
  • [Cites] Am J Physiol Renal Physiol. 2002 Aug;283(2):F309-18 [12110515.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2188-92 [12114419.001]
  • [Cites] J Anat. 2002 Jun;200(6):617-27 [12162729.001]
  • [Cites] J Anat. 2002 Jun;200(6):639-46 [12162731.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):96-103 [12672281.001]
  • [Cites] Lancet Neurol. 2003 Jul;2(7):404-9 [12849118.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2940-9 [12912940.001]
  • [Cites] J Pharm Sci. 1985 Feb;74(2):229-31 [3989700.001]
  • [Cites] Chem Pharm Bull (Tokyo). 1985 Apr;33(4):1620-32 [4042238.001]
  • [Cites] Biochem Biophys Res Commun. 1987 Oct 29;148(2):718-25 [3689368.001]
  • [Cites] Nature. 1988 Aug 25;334(6184):661-5 [3045562.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Cancer Res. 1989 Jun 15;49(12):3215-7 [2720675.001]
  • [Cites] Biochem Biophys Res Commun. 1989 Sep 29;163(3):1377-83 [2783141.001]
  • [Cites] Cancer Res. 1990 Feb 1;50(3):677-85 [2297708.001]
  • [Cites] Br J Cancer. 1992 Jul;66(1):10-9 [1637658.001]
  • [Cites] Pharmacol Ther. 1993 Sep;59(3):257-80 [8309991.001]
  • [Cites] J Biol Chem. 1994 Jun 10;269(23):16416-24 [7911467.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11762-6 [7972137.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;42(2):118-26 [9654111.001]
  • [Cites] Anal Biochem. 1996 Mar 1;235(1):36-43 [8850544.001]
  • (PMID = 15701280.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062475; United States / NCI NIH HHS / CA / U01-CA-26406; United States / NCI NIH HHS / CA / UO1CA-62475
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Oligonucleotides, Antisense; 0 / Phosphorothioate Oligonucleotides; EC 2.7.11.13 / PRKCA protein, human; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.13 / Protein Kinase C-alpha; FMT95051CQ / aprinocarsen
  • [Other-IDs] NLM/ PMC1871621
  •  go-up   go-down


18. Abdulazim A, Citak M, Backhaus M, Stienen MN, Horch C: Primary carcinoid tumor of the filum terminale--a case report. Acta Neurochir (Wien); 2010 Nov;152(11):1975-9
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary carcinoid tumor of the filum terminale--a case report.
  • Carcinoid tumors with a primary site in the central nervous system have not been reported in literature yet.
  • We report here about a 41-year-old patient with recurrent and progressive low back pain and bilateral S1 radiculopathy on admission.
  • The patient underwent hemi-laminectomies of the vertebral bodies L5 and S1 and an en bloc resection of the tumor.
  • Postoperative histopathological examination resulted in a well-differentiated intrathecal neuroendocrine tumor (carcinoid) of the terminal filum.
  • Postoperative staging showed no pathological abnormalities and no tumor recurrence after 6 months.
  • Even though rare, carcinoids should be considered as differential diagnosis of tumors occurring in the CNS.
  • [MeSH-major] Carcinoid Tumor / pathology. Cauda Equina / pathology. Low Back Pain / etiology. Radiculopathy / etiology. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Adult. Humans. Male

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20676702.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


19. Grimm S, Chamberlain MC: Adult primary spinal cord tumors. Expert Rev Neurother; 2009 Oct;9(10):1487-95

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult primary spinal cord tumors.
  • Primary spinal cord tumors represent 2-4% of all neoplasms of the CNS.
  • Resective surgery can usually be accomplished with spinal ependymomas owing to separation of tumor from spinal cord and, when complete, require no further therapy.
  • Chemotherapy is administered for recurrent primary spinal cord tumors without other options, that is, reoperation or re-irradiation.
  • Problematic, however, is the lack of clinical trials in general for these CNS tumors and for spinal cord tumors in particular.
  • Primary treatment is surgery in essentially all spinal cord tumors, and predictors of outcome include preoperative functional status, histological grade of tumor and extent of surgical resection.
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Neurosurgical Procedures. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19831838.001).
  • [ISSN] 1744-8360
  • [Journal-full-title] Expert review of neurotherapeutics
  • [ISO-abbreviation] Expert Rev Neurother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 82
  •  go-up   go-down


20. Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, Groshen S, Swenson S, Markland F, Gandara D, Scudder S, Morgan R, Chen H, Lenz HJ, Oza AM: Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol; 2008 Jan 1;26(1):76-82
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.
  • Inhibitors of VEGF suppress tumor growth in OC models.
  • Metronomic chemotherapy, defined as frequent administration of low doses of cytotoxic chemotherapy, suppresses tumor growth, possibly by inhibiting angiogenesis.
  • A phase II trial was conducted to evaluate the antitumor activity and adverse effects of bevacizumab and metronomic oral cyclophosphamide in women with recurrent OC.
  • Up to two different regimens for recurrent disease were allowed.
  • Bevacizumab-related toxicities included four episodes of gastrointestinal perforation or fistula, two episodes each of CNS ischemia and pulmonary hypertension, and one episode each of gastrointestinal bleeding and wound healing complication.
  • CONCLUSION: The combination of bevacizumab and metronomic cyclophosphamide is active in recurrent OC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Administration, Oral. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. California. Chicago. Cyclophosphamide / administration & dosage. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. E-Selectin / metabolism. Female. Humans. Middle Aged. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / metabolism. Peritoneal Neoplasms / pathology. Prognosis. Survival Rate. Thrombospondin 1 / metabolism. Treatment Outcome. Vascular Endothelial Growth Factor A / metabolism

  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18165643.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CM / CM-17102; United States / NCI NIH HHS / CM / CM17107; United States / NCI NIH HHS / CM / CM62203; United States / NCI NIH HHS / CM / N01 CM62209; United States / NCI NIH HHS / CA / P30 CA 14089
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / E-Selectin; 0 / Thrombospondin 1; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


21. Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH: Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer; 2007 Oct 1;110(7):1542-50
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
  • BACKGROUND: Effective chemotherapy is lacking for most types of central nervous system (CNS) tumors in children.
  • Temozolomide, an agent with activity against adult brain tumors, was investigated in children and adolescents with recurrent CNS tumors.
  • RESULTS: The cohort comprised 122 patients, including 113 with CNS tumors.
  • Among 104 evaluable patients with CNS tumors, 5 PRs and 1 CR were observed.
  • PRs occurred in 1 of 23 evaluable patients with high-grade astrocytoma, 1 of 21 with low-grade astrocytoma, and 3 of 25 with medulloblastoma/primitive neuroectodermal tumor (PNET).
  • No responses were observed in patients with ependymoma, brain-stem glioma, or other CNS tumors.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Astrocytoma / drug therapy. Central Nervous System Neoplasms / drug therapy. Child. Child, Preschool. Drug Administration Schedule. Ependymoma / drug therapy. Female. Humans. Infant. Male. Medulloblastoma / drug therapy. Neuroectodermal Tumors, Primitive / drug therapy. Treatment Outcome


22. Crawford JR, Santi MR, Cornelison R, Sallinen SL, Haapasalo H, MacDonald TJ: Detection of human herpesvirus-6 in adult central nervous system tumors: predominance of early and late viral antigens in glial tumors. J Neurooncol; 2009 Oct;95(1):49-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of human herpesvirus-6 in adult central nervous system tumors: predominance of early and late viral antigens in glial tumors.
  • The purpose is to determine the incidence of active and latent human herpesvirus-6 (HHV-6) infection in a large cohort of adult primary and recurrent CNS tumors.
  • We screened a tissue microarray (TMA) containing more than 200 adult primary and recurrent CNS tumors with known clinical information for the presence of HHV-6 DNA by in situ hybridization (ISH) and protein by immunohistochemistry (IHC).
  • One hundred six of 224 (47%) CNS tumors were positive for HHV-6 U57 Major Capsid Protein (MCP) gene by ISH compared to 0/25 non tumor control brain (P = 0.001).
  • Fourteen of 30 (47%) tumors were HHV-6 MCP positive by nested PCR compared to 0/25 non-tumor brain controls (P = 0.001), revealing HHV-6 Variant A in 6 of 14 samples.
  • HHV-6 p41 (P = 0.645) and gp116/64/54 (P = 0.198) antigen detection was independent of recurrent disease.
  • HHV-6 early and late antigens are detected in adult primary and recurrent CNS tumors more frequently in glial tumors.
  • We hypothesize that the glial-tropic features of HHV-6 may play an important modifying role in tumor biology that warrants further investigation.
  • [MeSH-major] Antigens, Viral. Central Nervous System Neoplasms / genetics. Central Nervous System Neoplasms / virology. Glioma / genetics. Glioma / virology. Herpesvirus 6, Human / isolation & purification
  • [MeSH-minor] Adult. Antigens, CD / metabolism. CD48 Antigen. Capsid Proteins / genetics. Capsid Proteins / metabolism. Humans. Survival Analysis. Viral Envelope Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19424665.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / K12NS052159-01A
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Viral; 0 / CD48 Antigen; 0 / Capsid Proteins; 0 / Viral Envelope Proteins
  •  go-up   go-down


23. Courts C, Montesinos-Rongen M, Brunn A, Bug S, Siemer D, Hans V, Blümcke I, Klapper W, Schaller C, Wiestler OD, Küppers R, Siebert R, Deckert M: Recurrent inactivation of the PRDM1 gene in primary central nervous system lymphoma. J Neuropathol Exp Neurol; 2008 Jul;67(7):720-7
Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent inactivation of the PRDM1 gene in primary central nervous system lymphoma.
  • Primary lymphomas of the CNS (PCNSLs) show molecular features of the late germinal center exit B-cell phenotype and are impaired in their terminal differentiation as indicated by a lack of immunoglobulin class switching.
  • Thus, similar to systemic diffuse large B-cell lymphomas, PRDM1 may be a tumor suppressor in some PCNSL and contribute to lymphomagenesis by impairing terminal differentiation.
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Gene Expression Regulation, Neoplastic / genetics. Lymphoma, B-Cell / genetics. Repressor Proteins / genetics. Sequence Deletion
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. DNA Mutational Analysis / methods. Female. Humans. Male. Middle Aged. Recurrence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18596541.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Repressor Proteins; 138415-26-6 / PRDM1 protein, human
  •  go-up   go-down


24. Neder L, Scheithauer BW, Turel KE, Arnesen MA, Ketterling RP, Jin L, Moynihan TJ, Giannini C, Meyer FB: Desmoplastic small round cell tumor of the central nervous system: report of two cases and review of the literature. Virchows Arch; 2009 Apr;454(4):431-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoplastic small round cell tumor of the central nervous system: report of two cases and review of the literature.
  • Desmoplastic small round cell tumor (DSRCT) is a malignant tumor often involving the abdominal and/or pelvic peritoneum.
  • Only one fully documented example has arisen in the central nervous system (CNS).
  • Patient 1, a 37-year-old male, underwent a subtotal resection, and 2 years later died of recurrent disease with spinal dissemination.
  • In conclusion, CNS DSRCT follows a similar aggressive course as do peritoneal examples.
  • Although rare, DSRCT warrants consideration in the differential diagnosis of "malignant small blue cell tumors" of the CNS.
  • [MeSH-minor] Adult. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Magnetic Resonance Imaging. Male. Oncogene Proteins, Fusion / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1992 Oct;16(10):998-1006 [1384373.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Am J Surg Pathol. 1998 Nov;22(11):1303-13 [9808123.001]
  • [Cites] Am J Surg Pathol. 1990 Jul;14(7):633-42 [2356923.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3028-36 [9738572.001]
  • [Cites] Diagn Mol Pathol. 1998 Feb;7(1):24-8 [9646031.001]
  • [Cites] Am J Surg Pathol. 1996 Jan;20(1):112-7 [8540602.001]
  • [Cites] Hum Pathol. 1997 Apr;28(4):502-9 [9104953.001]
  • [Cites] Cancer Cell. 2002 Dec;2(6):497-505 [12498718.001]
  • [Cites] Arch Pathol Lab Med. 2006 May;130(5):728-32 [16683894.001]
  • [Cites] Hum Pathol. 1992 Apr;23(4):454-64 [1563748.001]
  • [Cites] Arch Pathol Lab Med. 1989 Sep;113(9):1019-29 [2505732.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):823-35 [12131150.001]
  • [Cites] Am J Surg Pathol. 1989 May;13(5):413-21 [2469334.001]
  • [Cites] Nature. 1990 Jul 12;346(6280):194-7 [2164159.001]
  • [Cites] Am J Surg Pathol. 1995 Jun;19(6):659-65 [7755152.001]
  • [Cites] Diagn Mol Pathol. 2005 Mar;14(1):23-8 [15714060.001]
  • [Cites] Am J Surg Pathol. 1999 Nov;23(11):1408-13 [10555010.001]
  • [Cites] Cancer Genet Cytogenet. 1993 Aug;69(1):17-21 [8374894.001]
  • [Cites] Exp Cell Res. 2001 Mar 10;264(1):74-99 [11237525.001]
  • [Cites] Acta Cytol. 1995 Mar-Apr;39(2):377-8 [7887076.001]
  • [Cites] J Surg Oncol. 1999 Aug;71(4):269-72 [10440769.001]
  • [Cites] J Neurosurg. 1996 Jul;85(1):56-65 [8683283.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Acta Cytol. 1993 Jan-Feb;37(1):77-82 [7679537.001]
  • [Cites] Semin Diagn Pathol. 1996 Aug;13(3):204-12 [8875710.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):1028-32 [7862627.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):644-50 [15105654.001]
  • [Cites] Virchows Arch. 1998 Feb;432(2):135-41 [9504858.001]
  • [Cites] Mod Pathol. 1999 Jul;12(7):729-34 [10430278.001]
  • [Cites] Ultrastruct Pathol. 2000 Sep-Oct;24(5):333-7 [11071572.001]
  • [Cites] Hum Pathol. 1999 Apr;30(4):430-5 [10208465.001]
  • [Cites] Pediatr Pathol. 1989;9(2):177-83 [2473463.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1991;418(3):207-14 [1900966.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2837-40 [8187063.001]
  • [Cites] Am J Surg Pathol. 1991 Jun;15(6):499-513 [1709557.001]
  • [Cites] Gynecol Oncol. 2000 Oct;79(1):124-8 [11006044.001]
  • [Cites] Arch Pathol Lab Med. 2002 Oct;126(10):1226-8 [12296765.001]
  • [Cites] Semin Cancer Biol. 2005 Jun;15(3):197-205 [15826834.001]
  • [Cites] Semin Diagn Pathol. 2003 Feb;20(1):25-45 [12693673.001]
  • [Cites] Pediatr Blood Cancer. 2008 Oct;51(4):545-8 [18561179.001]
  • (PMID = 19263077.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / EWS1-WT1 fusion protein, human; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


25. Doyle DM, Einhorn LH: Delayed effects of whole brain radiotherapy in germ cell tumor patients with central nervous system metastases. Int J Radiat Oncol Biol Phys; 2008 Apr 1;70(5):1361-4
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delayed effects of whole brain radiotherapy in germ cell tumor patients with central nervous system metastases.
  • PURPOSE: Central nervous system (CNS) metastases are uncommon in patients with germ cell tumors, with an incidence of 2-3%.
  • CNS metastases have been managed with whole brain radiotherapy (WBRT) and concomitant cisplatin-based combination chemotherapy.
  • Our previous study did not observe serious CNS toxicity (Int J Radiat Oncol Biol Phys 1991;22:17-22).
  • We now report on 5 patients who developed delayed significant CNS toxicity.
  • PATIENTS AND METHODS: We observed 5 patients with delayed CNS toxicity.
  • Of the 5 patients, 3 had CNS metastases at diagnosis and 2 developed relapses with CNS metastases.
  • The median time from WBRT to CNS symptoms was 72 months (range, 9-228).
  • The progressive multifocal leukoencephalopathy resulted in significant debility in all 5 patients, resulting in death (3 patients), loss of work, steroid-induced morbidity, and recurrent hospitalizations.
  • CONCLUSION: Whole brain radiotherapy is not innocuous in young patients with germ cell tumors and can cause late CNS toxicity.
  • [MeSH-major] Brain / radiation effects. Brain Neoplasms / radiotherapy. Cranial Irradiation / adverse effects. Neoplasms, Germ Cell and Embryonal / radiotherapy. Radiation Injuries / complications. Testicular Neoplasms
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Choriocarcinoma / blood. Choriocarcinoma / drug therapy. Choriocarcinoma / radiotherapy. Choriocarcinoma / secondary. Chorionic Gonadotropin / blood. Cisplatin / administration & dosage. Combined Modality Therapy / adverse effects. Combined Modality Therapy / methods. Fatal Outcome. Humans. Leukoencephalopathy, Progressive Multifocal / etiology. Lung Neoplasms / secondary. Male. Neoplasm Proteins / blood. Radiotherapy Dosage. Salvage Therapy / methods. Stem Cell Transplantation. Time Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1300-2 [18374219.001]
  • (PMID = 18374223.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin; 0 / Neoplasm Proteins; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


26. Kieran MW, Packer RJ, Onar A, Blaney SM, Phillips P, Pollack IF, Geyer JR, Gururangan S, Banerjee A, Goldman S, Turner CD, Belasco JB, Broniscer A, Zhu Y, Frank E, Kirschmeier P, Statkevich P, Yver A, Boyett JM, Kun LE: Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. J Clin Oncol; 2007 Jul 20;25(21):3137-43
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study.
  • PURPOSE: A dose-escalation phase I and pharmacokinetic study of the farnesyltransferase inhibitor lonafarnib (SCH66336) was conducted in children with recurrent or progressive CNS tumors.
  • RESULTS: Fifty-three children with progressive or recurrent brain tumors were enrolled, with a median age of 12.2 years (range, 3.9 to 19.5 years).
  • [MeSH-major] Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / mortality. Enzyme Inhibitors / pharmacokinetics. Farnesyltranstransferase / antagonists & inhibitors. Neoplasm Invasiveness / pathology. Piperidines / pharmacokinetics. Pyridines / pharmacokinetics
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Child. Child, Preschool. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Male. Maximum Tolerated Dose. Neoplasm Staging. Risk Assessment. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17634493.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA81457
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Piperidines; 0 / Pyridines; 193275-84-2 / lonafarnib; EC 2.5.1.29 / Farnesyltranstransferase
  •  go-up   go-down


27. Lasky JL 3rd, Choe M, Nakano I: Cancer stem cells in pediatric brain tumors. Curr Stem Cell Res Ther; 2009 Dec;4(4):298-305
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer stem cells in pediatric brain tumors.
  • Central nervous system (CNS) tumors remain the leading cause of death among pediatric neoplasms.
  • Although standard therapies cure many pediatric CNS tumors, the long-term cognitive and physical consequences of these therapies are devastating.
  • Furthermore, recurrent disease carries a dismal prognosis.
  • Although recent studies have focused on molecular mechanisms that underlie the initiation and progression of adult glioblastoma multiforme (GBM), these tumors differ phenotypically and at a molecular level from pediatric brain tumors.
  • Recent investigations have identified a stem cell population, termed "brain tumor stem cells" (BTSC) within the heterogeneous cell populations that comprise malignant brain tumors which may be partly responsible for the resistance to current therapies.
  • By exploiting molecular differences present within these heterogeneous populations of brain tumor cells, we may be able to achieve specific eradication of BTSC and long-lasting remissions, while causing less toxicity to normal tissues.
  • In this review, we describe the issues surrounding the identification and characterization of BTSC, the molecular biology of BTSC for different pediatric brain tumors, and suggest future avenues for the development of treatments for this devastating disease.
  • [MeSH-major] Brain Neoplasms / pathology. Ependymoma / pathology. Medulloblastoma / pathology. Neoplastic Stem Cells / pathology. Optic Nerve Glioma / pathology
  • [MeSH-minor] Adult Stem Cells / pathology. Biomarkers / metabolism. Cell Differentiation. Chemotherapy, Adjuvant. Child. Humans. Surgical Procedures, Operative


28. Rajaram V, Gutmann DH, Prasad SK, Mansur DB, Perry A: Alterations of protein 4.1 family members in ependymomas: a study of 84 cases. Mod Pathol; 2005 Jul;18(7):991-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ependymomas are common pediatric and adult CNS malignancies with a wide biologic spectrum that is often hard to predict using classic prognostic variables.
  • The majority of cases harbored one or more detectable genetic alterations, but we found that 4.1B gene deletions and 4.1R loss of expression were statistically more common in the pediatric vs adult, intracranial vs spinal, and grade III vs grade I/II subsets (P-values of 0.038 to <0.001).
  • Also, 4.1G deletions were seen in 11/27 (41%) patients who either died of disease or had residual/recurrent tumor vs 5/41 patients with no evidence of disease at last follow-up (P=0.009).
  • [MeSH-minor] Adolescent. Adult. Aged. Blood Proteins / analysis. Blood Proteins / genetics. Brain Neoplasms / genetics. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Child. Child, Preschool. Cohort Studies. Cytoskeletal Proteins / analysis. Cytoskeletal Proteins / genetics. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Infant. Microfilament Proteins. Microtubule-Associated Proteins / analysis. Microtubule-Associated Proteins / genetics. Middle Aged. Neurofibromin 2 / analysis. Neurofibromin 2 / genetics. Spinal Cord Neoplasms / genetics. Spinal Cord Neoplasms / metabolism. Spinal Cord Neoplasms / pathology. Tumor Suppressor Proteins / analysis. Tumor Suppressor Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15731777.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Proteins; 0 / Cytoskeletal Proteins; 0 / EPB41L3 protein, human; 0 / Membrane Proteins; 0 / Microfilament Proteins; 0 / Microtubule-Associated Proteins; 0 / Neurofibromin 2; 0 / Tumor Suppressor Proteins; 0 / erythrocyte membrane band 4.1 protein
  •  go-up   go-down


29. Ribi C, Sztajzel R, Delavelle J, Chizzolini C: Efficacy of TNF {alpha} blockade in cyclophosphamide resistant neuro-Behçet disease. J Neurol Neurosurg Psychiatry; 2005 Dec;76(12):1733-5
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Behçet disease is a chronic relapsing inflammatory condition, predominantly affecting young adults, characterised by recurrent bipolar aphtae and systemic manifestations for which tumour necrosis factor (TNF) alpha blockade has recently emerged as an effective treatment.
  • We report the case of a patient presenting with mucocutaneous and ocular manifestations who in the course of his disease developed CNS parenchymal involvement.
  • While being treated with pulsed cyclophosphamide and corticosteroids, he suffered a relapse of his CNS involvement that was efficaciously controlled by infliximab.
  • However, 7 months after the last administration of infliximab and still under immunosuppressant agents, CNS lesions recurred.
  • [MeSH-minor] Adult. Cyclophosphamide / pharmacology. Cyclophosphamide / therapeutic use. Humans. Immunosuppressive Agents / pharmacology. Immunosuppressive Agents / therapeutic use. Infliximab. Male. Treatment Outcome. Tumor Necrosis Factor-alpha / antagonists & inhibitors

  • Genetic Alliance. consumer health - Behcet's Disease.
  • MedlinePlus Health Information. consumer health - Behcet's Syndrome.
  • Hazardous Substances Data Bank. Infliximab .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16291906.001).
  • [ISSN] 0022-3050
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antirheumatic Agents; 0 / Immunosuppressive Agents; 0 / Tumor Necrosis Factor-alpha; 8N3DW7272P / Cyclophosphamide; B72HH48FLU / Infliximab
  • [Other-IDs] NLM/ PMC1739470
  •  go-up   go-down


30. Arita H, Izumoto S, Kinoshita M, Okita Y, Hashimoto N, Fujita T, Ichimaru N, Takahara S, Yoshimine T: Posttransplant lymphoproliferative disorders of the central nervous system after kidney transplantation: single center experience over 40 years. Two case reports. Neurol Med Chir (Tokyo); 2010;50(12):1079-83
Hazardous Substances Data Bank. MYCOPHENOLATE MOFETIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Posttransplant lymphoproliferative disorders of the central nervous system after kidney transplantation: single center experience over 40 years. Two case reports.
  • PTLD sometimes involves the central nervous system (CNS), but the clinical characteristics are not well recognized.
  • Two of the 631 patients (0.32%) developed CNS PTLD.
  • A 40-year-old Japanese woman suffered onset of CNS PTLD 5 years after renal transplantation.
  • She underwent second biopsy and the diagnosis was recurrent CNS PTLD.
  • A 61-year-old woman suffered onset of CNS PTLD 19 years after renal transplantation.
  • After tumor removal, whole brain irradiation was performed.
  • The first case of polymorphic CNS PTLD was successfully treated by modulation of immunosuppressants without radiation therapy even at recurrence.
  • PTLD should be included in the differential diagnosis of brain tumors in recipients of solid organ transplantation, and histological subtype should be carefully identified to establish the correct treatment strategy.
  • [MeSH-major] Central Nervous System Diseases / pathology. Immunosuppressive Agents / adverse effects. Kidney Transplantation / adverse effects. Lymphoproliferative Disorders / pathology
  • [MeSH-minor] Adult. B-Lymphocytes / pathology. Dose-Response Relationship, Drug. Female. Humans. Middle Aged. Mycophenolic Acid / administration & dosage. Mycophenolic Acid / analogs & derivatives. Steroids / administration & dosage. Steroids / adverse effects. T-Lymphocytes / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21206182.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / Steroids; 9242ECW6R0 / mycophenolate mofetil; HU9DX48N0T / Mycophenolic Acid
  •  go-up   go-down


31. Mangels KJ, Johnson MD, Weil RJ: 35-year-old woman with progressive bilateral leg weakness. Brain Pathol; 2006 Apr;16(2):183-4, 187

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At surgery an intradural, extramedullary, firm, black neoplasm was encountered, which invaded the ventral dura and elevated and distorted the spinal cord.
  • Serial sections revealed a homogeneous black tumor without necrosis.
  • H&E stained sections showed an occasionally fascicular tumor of melanocytes and small round blue tumor spindle cells with melanin pigmentation and 1-2 mitotic figures per 10 high-powered fields.
  • A diagnosis of primary meningeal melanocytic tumor was made.
  • PMMTs of the CNS consist of a spectrum of tumors ranging from well-differentiated melanocytoma to its overtly malignant counterpart, melanoma.
  • Once metastasis, including drop metastasis from pigmented medulloblastomas, have been excluded, the differential includes pigmented meningiomas and schwannomas (solitary or as part of Carney complex), as well as other pigmented CNS tumors such as ependymoma and pineoblastoma and systemic diseases such as lymphoma . . .
  • For primary CNS melanocytic neoplasms, complete tumor resection is preferred, as it leads to cure of well-differentiated and intermediate-grade melanocytomas and most melanomas.
  • Radiotherapy is recommended for incomplete resection of IMGs and melanomas; the recurrence potential of low-grade melanocytomas is less clear and watchful waiting may be employed, since recurrent tumors may be treated surgically prior to radiation.
  • [MeSH-minor] Adult. Female. Functional Laterality. Humans. Thoracic Vertebrae. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16768759.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


32. Olson C, Yen CP, Schlesinger D, Sheehan J: Radiosurgery for intracranial hemangiopericytomas: outcomes after initial and repeat Gamma Knife surgery. J Neurosurg; 2010 Jan;112(1):133-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: Intracranial hemangiopericytoma is a rare CNS tumor that exhibits a high incidence of local recurrence and distant metastasis.
  • METHODS: In a review of the University of Virginia radiosurgery database between 1989 and 2008, the authors found recurrent or residual hemangiopericytomas after resection in 21 patients in whom radiosurgery was performed to treat 28 discrete tumors.
  • RESULTS: At last follow-up, local tumor control was demonstrated in 47.6% of the patients (10 of 21 patients) with hemangiopericytomas.
  • Prior fractionated irradiation or radiosurgical prescription dose did not correlate with tumor control.
  • CONCLUSIONS: Radiosurgery is a reasonable treatment option for recurrent hemangiopericytomas.
  • Repeat radiosurgery may be used to treat new or recurrent hemangiopericytomas over a long follow-up course.
  • [MeSH-major] Brain Neoplasms / surgery. Hemangiopericytoma / surgery. Neoplasm Recurrence, Local / surgery. Radiosurgery / methods
  • [MeSH-minor] Adult. Craniotomy / methods. Disease Progression. Embolization, Therapeutic. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Metastasis. Radiotherapy / methods. Radiotherapy Dosage. Sphenoid Bone / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19392594.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Iwanami H, Odaka M, Hirata K: [A case of acute lymphocytic leukemia relapsed as meningoradiculoneuropathy after bone marrow transplantation]. Rinsho Shinkeigaku; 2006 Feb;46(2):157-9
MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of acute lymphocytic leukemia relapsed as meningoradiculoneuropathy after bone marrow transplantation].
  • We report a 21-year-old woman who had acute lymphocytic leukemia with a relapse in the peripheral nervous system after bone marrow transplantation.
  • Based on the diagnosis of recurrent acute lymphocytic leukemia with tumor infiltration to the meninges (meningeal leukemia), she received chemotherapy, after which her neurological symptoms and signs gradually improved.
  • We would like to emphasize that neurological examination is important to detect CNS relapse in a patient with leukemia, even in hematological complete remission.
  • [MeSH-major] Bone Marrow Transplantation. Meningeal Neoplasms / etiology. Peripheral Nervous System Neoplasms / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Female. Humans. Polyradiculoneuropathy / etiology. Recurrence

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619843.001).
  • [ISSN] 0009-918X
  • [Journal-full-title] Rinshō shinkeigaku = Clinical neurology
  • [ISO-abbreviation] Rinsho Shinkeigaku
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


34. Bhattacharyya I, Chehal HK, Cohen DM, Al-Quran SZ: Primary diffuse large B-cell lymphoma of the oral cavity: germinal center classification. Head Neck Pathol; 2010 Sep;4(3):181-91
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Studies validating this classification have been done for DLBCL of the breast, CNS, testes and GI tract.
  • Four of the 5 patients in the GCB subgroup were alive with no evidence of disease and one patient succumbed to complications of therapy and recurrent disease after 18 months.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. DNA-Binding Proteins / metabolism. Disease-Free Survival. Fatal Outcome. Female. Humans. Immunohistochemistry. Interferon Regulatory Factors / metabolism. Ki-67 Antigen / metabolism. Male. Middle Aged. Neprilysin / metabolism. Prognosis. Proto-Oncogene Proteins c-bcl-2 / metabolism

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 1998 Aug;25(4):483-91 [9728598.001]
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1):117-22 [9894462.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):423-9 [10458261.001]
  • [Cites] Virchows Arch. 2004 Dec;445(6):545-51 [15517363.001]
  • [Cites] Mod Pathol. 2005 Mar;18(3):398-405 [15492762.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Mar;99(3):303-10 [15716836.001]
  • [Cites] Cancer. 2006 Jan 15;106(2):247-57 [16342164.001]
  • [Cites] Mod Pathol. 2006 Dec;19(12):1521-7 [16998463.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):447-54 [18086797.001]
  • [Cites] Hematology. 2009 Apr;14(2):84-9 [19298719.001]
  • [Cites] Cancer Sci. 2009 Oct;100(10):1842-7 [19656156.001]
  • [Cites] Mod Pathol. 2010 Feb;23(2):235-43 [19935644.001]
  • [Cites] Blood. 2000 Jan 15;95(2):651-9 [10627476.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Blood. 2000 Mar 1;95(5):1797-803 [10688840.001]
  • [Cites] Blood. 2000 Mar 15;95(6):2084-92 [10706878.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):846-52 [10843287.001]
  • [Cites] Immunity. 2000 Aug;13(2):199-212 [10981963.001]
  • [Cites] Mod Pathol. 2000 Nov;13(11):1244-52 [11106083.001]
  • [Cites] Mod Pathol. 2001 Feb;14(2):105-10 [11235901.001]
  • [Cites] Curr Opin Oncol. 2001 Sep;13(5):325-34 [11555708.001]
  • [Cites] Leuk Lymphoma. 2001 Sep-Oct;42(5):1089-98 [11697626.001]
  • [Cites] Nat Med. 2002 Jan;8(1):68-74 [11786909.001]
  • [Cites] Hum Pathol. 2002 Feb;33(2):153-7 [11957138.001]
  • [Cites] Br J Haematol. 2002 May;117(2):322-32 [11972514.001]
  • [Cites] N Engl J Med. 1987 Nov 5;317(19):1185-9 [3657890.001]
  • [Cites] J Pathol. 1988 Mar;154(3):223-35 [2450981.001]
  • [Cites] J Clin Pathol. 1989 Nov;42(11):1194-200 [2531171.001]
  • [Cites] Am J Pathol. 1990 Aug;137(2):225-32 [2201196.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1190-7 [2205355.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):231-6 [8508412.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Science. 1993 Oct 29;262(5134):747-50 [8235596.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Mod Pathol. 2002 Aug;15(8):807-16 [12181265.001]
  • [Cites] Mod Pathol. 2002 Dec;15(12):1366-73 [12481019.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):722-8 [12576441.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1063-9 [12631608.001]
  • [Cites] Am J Surg Pathol. 2003 Sep;27(9):1269-77 [12960812.001]
  • [Cites] Histopathology. 2003 Dec;43(6):509-28 [14636252.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3498-506 [15337798.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):5948-55 [15342373.001]
  • [Cites] J Clin Oncol. 1987 Mar;5(3):407-12 [3819806.001]
  • [Cites] Ann Intern Med. 1987 Jul;107(1):25-30 [3296898.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1994;30B(2):121-5 [8032301.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Am J Pathol. 1996 May;148(5):1543-55 [8623923.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996 Aug;82(2):173-8 [8863307.001]
  • (PMID = 20533006.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Interferon Regulatory Factors; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / interferon regulatory factor-4; EC 3.4.24.11 / Neprilysin
  • [Other-IDs] NLM/ PMC2923304
  •  go-up   go-down


35. Schneider DT, Zahn S, Sievers S, Alemazkour K, Reifenberger G, Wiestler OD, Calaminus G, Göbel U, Perlman EJ: Molecular genetic analysis of central nervous system germ cell tumors with comparative genomic hybridization. Mod Pathol; 2006 Jun;19(6):864-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular genetic analysis of central nervous system germ cell tumors with comparative genomic hybridization.
  • The limited information available to date regarding the genetic alterations in germ cell tumors of the central nervous system has raised concerns about their biologic relationship to other germ cell tumor entities.
  • We investigated fresh-frozen or archival tumor samples from 19 patients with central nervous system germ cell tumors (CNS-GCTs), including seven germinomas, eight malignant nongerminomatous germ cell tumors and four teratomas, using chromosomal comparative genomic hybridization to determine recurrent chromosomal imbalances.
  • All 15 malignant CNS-GCTs and two of four teratomas showed multiple chromosomal imbalances.
  • Chromosomal gains (median: 4 gains/tumor, range: 0-9 gains/tumor) were observed more frequently than losses (median: 1.6 losses/tumor, range: 0-6 losses/tumor).
  • Gain of 12p, which is considered characteristic for germ cell tumors of the adult testis, was detected in 11 of 19 tumors and 10 of 15 malignant CNS-GCTs.
  • In one tumor, gain of 12p was confined to an amplicon at 12p12, corresponding to the commonly amplified region on 12p.
  • Notably, we observed no difference in the genetic profiles of germinomatous and nongerminomatous CNS-GCTs; however, the average number of imbalances was higher in the latter group.
  • A meta-analysis comparing 116 malignant gonadal and extragonadal germ cell tumors revealed that the genomic alterations in CNS-GCTs are virtually indistinguishable from those found in their gonadal or other extragonadal counterparts of the corresponding age group.
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Genetic Testing / methods. Neoplasms, Germ Cell and Embryonal / genetics. Oligonucleotide Array Sequence Analysis / methods
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. DNA, Neoplasm / analysis. Female. Humans. Infant, Newborn. Male. Meta-Analysis as Topic

  • MedlinePlus Health Information. consumer health - Genetic Testing.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607373.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


36. Yoshikata R, Yamamoto T, Kobayashi M, Ota H: Immunohistochemical characteristics of mature ovarian cystic teratomas in patients with postoperative recurrence. Int J Gynecol Pathol; 2006 Jan;25(1):95-100
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The recurrence group was generally younger (mean, 22.9 +/- 1.26 vs. 32.8 +/- 1.15 years; p < 0.05), had higher tridermal components, and had greater central nervous system (CNS) component expression rate (9 vs. 48%, p < 0.05) compared with the non-recurrence group.
  • The presence of tridermal components and a high synaptophysin/glial fibrillary acidic protein (SP/GFAP) ratio suggested that recurrent ovarian teratomas were capable of both neuronal and glial differentiations.
  • [MeSH-major] Neoplasm Recurrence, Local. Ovarian Neoplasms / chemistry. Teratoma / chemistry
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / analysis. Female. Fluorescent Antibody Technique, Indirect. Glial Fibrillary Acidic Protein / analysis. Humans. Intermediate Filament Proteins / analysis. Nerve Tissue Proteins / analysis. Nestin. Neuroglia / pathology. Neurons / pathology. Synaptophysin / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16306792.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / Synaptophysin
  •  go-up   go-down


37. Rousseau A, Kujas M, Bergemer-Fouquet AM, van Effenterre R, Hauw JJ: Survivin expression in ganglioglioma. J Neurooncol; 2006 Apr;77(2):153-9
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gangliogliomas are unusual central nervous system (CNS) neoplasms occurring mainly in children and young adults and inducing chronic pharmacoresistant epilepsy.
  • Survivin expression in more than 5% neoplastic glial cells was detected only in malignant and/or recurrent gangliogliomas.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Ganglioglioma / metabolism. Ganglioglioma / pathology. Microtubule-Associated Proteins / biosynthesis. Neoplasm Proteins / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Immunohistochemistry. Infant. Inhibitor of Apoptosis Proteins. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Ganglioglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16292482.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


38. Kim CY, Paek SH, Jeong SS, Chung HT, Han JH, Park CK, Jung HW, Kim DG: Gamma knife radiosurgery for central neurocytoma: primary and secondary treatment. Cancer; 2007 Nov 15;110(10):2276-84
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma knife radiosurgery for central neurocytoma: primary and secondary treatment.
  • BACKGROUND: Little is known about long-term results of gamma knife (GK) stereotactic radiosurgery (SRS) as a primary or a secondary postoperative therapy for central neurocytomas (CNs).
  • Follow-up clinical status and brain magnetic resonance imaging (MRI) were thoroughly analyzed.
  • However, the tumor recurred in 2 patients treated with a secondary GK SRS after surgery from the residual tumor bed that was not covered by the GK SRS.
  • However, more attention should be paid to residual or recurrent CN during treatment, and regular long-term follow-up MRI should be mandatory to validate the procedure.
  • [MeSH-major] Brain Neoplasms / surgery. Neurocytoma / surgery. Radiosurgery
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Central Neurocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society.
  • (PMID = 17926332.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


39. Mut M, Güler-Tezel G, Lopes MB, Bilginer B, Ziyal I, Ozcan OE: Challenging diagnosis: oligodendroglioma versus extraventricular neurocytoma. Clin Neuropathol; 2005 Sep-Oct;24(5):225-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnosis of oligodendroglioma from other clear cell neoplasms of central nervous system (CNS) is still challenging despite advances in neuroradiology and molecular diagnostic tools.
  • He presented with intratumoral hemorrhage and he underwent radical resection of tumor in 2003.
  • Histopathological examination of the recurrent tumor showed anaplastic progression with confusing immunohistochemical (IHC) results; the tumor was positive for NeuN and synaptophysin staining.
  • The question arisen was whether the recurrent tumor was an oligodendroglioma with neuronal differentiation or an extraventricular neurocytoma initially misdiagnosed as oligodendroglioma.
  • Current diagnostic methods of oligodendroglial tumors are discussed in context of differentiating oligodendrogliomas from other clear cell neoplasms of CNS, especially from extraventricular neurocytomas.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neurocytoma / pathology. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Diagnosis, Differential. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Magnetic Resonance Imaging. Male. Nerve Tissue Proteins / biosynthesis. Synaptophysin / biosynthesis

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16167546.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins; 0 / Synaptophysin
  •  go-up   go-down






Advertisement